Compare with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES LUPIN ALKEM LABORATORIES/
LUPIN
 
P/E (TTM) x 22.4 41.5 54.1% View Chart
P/BV x 5.4 3.8 142.1% View Chart
Dividend Yield % 0.9 0.6 157.7%  

Financials

 ALKEM LABORATORIES   LUPIN
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
LUPIN
Mar-20
ALKEM LABORATORIES/
LUPIN
5-Yr Chart
Click to enlarge
High Rs2,720882 308.3%   
Low Rs1,660505 328.8%   
Sales per share (Unadj.) Rs697.9339.4 205.6%  
Earnings per share (Unadj.) Rs96.1-5.9 -1,616.3%  
Cash flow per share (Unadj.) Rs117.315.5 757.9%  
Dividends per share (Unadj.) Rs25.006.00 416.7%  
Dividend yield (eoy) %1.10.9 132.0%  
Book value per share (Unadj.) Rs515.2276.7 186.2%  
Shares outstanding (eoy) m119.57453.00 26.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.0 153.6%   
Avg P/E ratio x22.8-116.6 -19.5%  
P/CF ratio (eoy) x18.744.8 41.7%  
Price / Book Value ratio x4.32.5 169.6%  
Dividend payout %26.0-100.9 -25.8%   
Avg Mkt Cap Rs m261,879314,201 83.3%   
No. of employees `00014.318.3 78.3%   
Total wages/salary Rs m15,05529,868 50.4%   
Avg. sales/employee Rs Th5,822.68,400.6 69.3%   
Avg. wages/employee Rs Th1,050.51,632.0 64.4%   
Avg. net profit/employee Rs Th802.0-147.2 -544.9%   
INCOME DATA
Net Sales Rs m83,444153,748 54.3%  
Other income Rs m1,0424,838 21.5%   
Total revenues Rs m84,486158,585 53.3%   
Gross profit Rs m14,73424,849 59.3%  
Depreciation Rs m2,5289,702 26.1%   
Interest Rs m6513,630 17.9%   
Profit before tax Rs m12,59816,355 77.0%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m1,10511,571 9.5%   
Profit after tax Rs m11,493-2,694 -426.6%  
Gross profit margin %17.716.2 109.3%  
Effective tax rate %8.870.8 12.4%   
Net profit margin %13.8-1.8 -786.1%  
BALANCE SHEET DATA
Current assets Rs m54,960154,132 35.7%   
Current liabilities Rs m32,43392,252 35.2%   
Net working cap to sales %27.040.2 67.1%  
Current ratio x1.71.7 101.4%  
Inventory Days Days8082 96.9%  
Debtors Days Days72129 55.8%  
Net fixed assets Rs m32,71089,082 36.7%   
Share capital Rs m239906 26.4%   
"Free" reserves Rs m61,368124,461 49.3%   
Net worth Rs m61,607125,367 49.1%   
Long term debt Rs m1,59217,933 8.9%   
Total assets Rs m99,433249,839 39.8%  
Interest coverage x20.45.5 369.9%   
Debt to equity ratio x00.1 18.1%  
Sales to assets ratio x0.80.6 136.4%   
Return on assets %12.20.4 3,260.2%  
Return on equity %18.7-2.1 -868.2%  
Return on capital %21.08.7 240.2%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06151,450 31.2%   
Fx outflow Rs m2,48319,470 12.8%   
Net fx Rs m13,57831,980 42.5%   
CASH FLOW
From Operations Rs m5,85114,688 39.8%  
From Investments Rs m-7,41411,070 -67.0%  
From Financial Activity Rs m792-8,906 -8.9%  
Net Cashflow Rs m-73116,853 -4.3%  

Share Holding

Indian Promoters % 66.9 46.6 143.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 33.1 11.3 292.9%  
FIIs % 0.0 31.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.1 -  
Shareholders   68,381 98,259 69.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  J.B.CHEMICALS  ORCHID PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Apr 16, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS